Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a public company limited by shares in China, has announced a Board meeting scheduled for August 28, 2024. The agenda includes reviewing and approving the interim results for the first half of the year and discussing potential interim dividend payments. The announcement was made by Chairman and CEO Shen Yuelei on behalf of the Board, which consists of a mix of executive, non-executive, and independent directors.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.
